NL-OMON33210已完成4 期
Can dipyridamole induce protection against ischemia and reperfusion injury in patients undergoing elective CABG? - CABG
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 130 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Acceptation for CABG in RUNMC
- •- Informed consent
排除标准
- •- Recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to
- •- Use of insulin
- •- Use of sulfonylurea derivates (e.g. glibenclamide, tolbutamide, gliclazide, glimepiride)
- •- Use of metformin
- •- Use of oral corticosteroids
- •- Use of dipyridamole
- •- Use of clopidogrel within 8 days prior to scheduled CABG surgery
- •- Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAIDs)
研究者
相似试验
进行中（未招募）
不适用
Can dipyridamole induce protection against ischemia and reperfusion injury in patients undergoing elective CABG?Ischemia reperfusion injury sustained during coronary bypass surgeryMedDRA version: 12.0Level: LLTClassification code 10006894Term: CABGMedDRA version: 12.0Level: LLTClassification code 10051624Term: Myocardial reperfusion injuryEUCTR2009-014299-22-NLRUNMC
已完成
4 期
Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?Ischemic Heart DiseaseCardiovascular DiseaseNCT01295567Radboud University Medical Center95
进行中（未招募）
1 期
The effect of dipyridamole on the pharmacokinetics of metformin.The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or stroke. Gastrointestinal absorption of metformin is mediated by the equilibrative nucleoside transporter 4 (hENT4). Dipyridamole has been reported to inhibit hENT4 transport in vitro. Dipyridamole may therefore negatively influence the uptake of metformin from the gastrointestinal tract.MedDRA version: 14.1Level: PTClassification code 10068071Term: Inhibitory drug interactionSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 14.1Level: PTClassification code 10013710Term: Drug interactionSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2012-000363-24-NLRadboud University Medical Centre Nijmegen18
招募中
4 期
The effect of dipyridamole on the pharmacokinetics of metformin.geneesmiddeleninteractieDrug interactionNL-OMON37582niversitair Medisch Centrum Sint Radboud18
尚未招募
4 期
Does short dipyridamole administration induce protection against ischemia-reperfusion injury?infarctionischemia reperfusion injury1001108210003216NL-OMON31190niversitair Medisch Centrum Sint Radboud10